Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Receivables - Other: 2020-2025

Historic Receivables - Other for Biofrontera (BFRI) over the last 2 years, with Mar 2025 value amounting to $200,000.

  • Biofrontera's Receivables - Other rose 16.96% to $200,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $200,000, marking a year-over-year increase of 16.96%. This contributed to the annual value of $2.8 million for FY2023, which is 56.92% down from last year.
  • Per Biofrontera's latest filing, its Receivables - Other stood at $200,000 for Q1 2025, which was up 16.96% from $171,000 recorded in Q1 2024.
  • Biofrontera's Receivables - Other's 5-year high stood at $8.7 million during Q1 2022, with a 5-year trough of $56,000 in Q3 2021.
  • For the 3-year period, Biofrontera's Receivables - Other averaged around $2.3 million, with its median value being $2.8 million (2023).
  • Its Receivables - Other has fluctuated over the past 5 years, first spiked by 11,745.21% in 2021, then tumbled by 95.44% in 2024.
  • Quarterly analysis of 5 years shows Biofrontera's Receivables - Other stood at $8.6 million in 2021, then fell by 24.83% to $6.5 million in 2022, then crashed by 56.92% to $2.8 million in 2023, then tumbled by 95.44% to $171,000 in 2024, then rose by 16.96% to $200,000 in 2025.
  • Its Receivables - Other stands at $200,000 for Q1 2025, versus $171,000 for Q1 2024 and $2.8 million for Q4 2023.